Fig. 1: Shallow deletion of the major components of the Hippo signaling cascade is associated with a poor prognosis in pRCC patients.
From: Targeting the disrupted Hippo signaling to prevent neoplastic renal epithelial cell immune evasion
pRCC patient clinical data and gene expression profiling data were extracted from the TCGA datasets (TCGA firehose study) and analyzed using the GraphPad Prism 9 software. A Copy number variation (CNV) of genes encoding the key components of the Hippo signaling pathway (n = 293). B Deletion (both deep & shallow deletions) of genes encoding the major components of the Hippo signaling cascade predicts poor overall survival in pRCC patients. del: deletion; dip: diploid. Data were analyzed using the Kaplan-Meier simple survival analysis with the Mantel-Cox test and Gehan-Breslow-Wilcoxon test. The P value of each comparison is presented on the top of the corresponding graph. C Deletion of genes encoding the key components of the Hippo signaling pathway is associated with dysregulation of known regulators of the pRCC development (e.g., CCNE1 and VHL, etc.). Data were analyzed with unpaired t-tests (two-tailed). The P value of each comparison is presented on the top of the corresponding graph (FAT1-dip: n = 174; FAT1-Del: n = 23; LATS2-Dip: n = 170; LATS2-Del: n = 20; NF2-Dip: n = 159; NF2-Del: n = 51). D Dysregulated CCNE1 and VHL is associated with poor patient survival rate. Data were analyzed using the Kaplan-Meier simple survival analysis with the Mantel-Cox test and Gehan-Breslow-Wilcoxon test. The P value of each comparison is presented on the top of the corresponding graph (CCNE1-high: n = 42, CCNE1-low: n = 153; VHL-high: n = 132, VHL-low: n = 28). E, F Deletion of the upstream suppressor of the Hippo signaling pathway and dysregulation of their downstream genes (e.g., CCNE1, VHL, etc.) are associated with pRCC progression. Source data are provided as a Source Data file.
